|
[1]
|
Garcia-Carretero, R., Vigil-Medina, L., Barquero-Perez, O., et al. (2017) Cystatin C as a Predictor of Cardiovascular Outcomes in a Hypertensive Population. Journal of Human Hypertension, 31, 801-807. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版) [J]. 中国实用内科杂志, 2018, 38(4): 292-344.
|
|
[3]
|
易小林. 血清胱抑素C检验在肾脏疾病中的临床价值[J]. 临床合理用药杂志, 2020, 13(34): 155-156.
|
|
[4]
|
张莉, 杨依萌, 冷吉燕, 等. 老年冠心病患者血尿酸及左室质量指数与冠状动脉病变程度的相关性[J]. 中国老年学杂志, 2017, 37(24): 6067-6069.
|
|
[5]
|
曹丽萍, 赵国忠, 何敏, 等. 2型糖尿病早期肾损害与心室重构的关系研究[J]. 实用预防医学, 2017, 24(5): 544-547.
|
|
[6]
|
Taglieri, N., Koenig, W. and Kaski, J.C. (2009) Cystatin C and Cardiovascular Risk. Clinical Chemistry, 55, 1932-1943. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
李拜红, 王晓彦. 血清胱抑素C对慢性心力衰竭诊断及疗效评估相关性研究[J]. 中西医结合心血管病电子杂志, 2019, 7(29): 70-76.
|
|
[8]
|
Bargnoux, A.-S., et al. (2019) Estimation of Glomerular Filtration Rate Using Cystatin C. Annales de Biologie Clinique, 77, 375-380. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Mallikethi-Reddy, S., Briasoulis, A., Akintoye, E., et al. (2017) Novel Biomarkers with Potential for Cardiovascular Risk Reclassification. Biomarkers, 22, 1-32. [Google Scholar] [CrossRef]
|
|
[10]
|
Cheng, X.W., Obata, K., Kuzuya, M., et al. (2006) Elastolytic Cathepsin Induction/Activation System Exists in Myocardium and Is Upregulated in Hypertensive Heart Failure. Hypertension, 48, 979-987. [Google Scholar] [CrossRef]
|
|
[11]
|
Balko, J.A., Gupta, S., Mammen, P.P.A., et al. (2009) Association of Cystatin C with Left Ventricular Structure and Function: The Dallas Heart Study. Circulation Heart Failure, 2, 98. [Google Scholar] [CrossRef]
|
|
[12]
|
Li, X., Zhu, H., Li, P., et al. (2013) Serum Cystatin C Concentration as an Independent Marker for Hypertensive Left Ventricular Hypertrophy. Journal of Geriatric Cardiology, 10, 286-290.
|
|
[13]
|
何芳, 田国平. 血清胱抑素C与慢性心力衰竭的研究进展[J]. 西南军医, 2019, 21(2): 150-153.
|
|
[14]
|
姜巍娇, 焦凯, 李春峰, 等. 糖尿病慢性心力衰竭患者血清胱抑素C水平与心室重构的相关性研究[J]. 糖尿病新世界, 2016, 19(24): 12-13.
|